Statements (55)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:vaccine
|
| gptkbp:approves |
gptkb:2005
gptkb:FDA |
| gptkbp:clinical_trial |
Phase III
ongoing studies prevent seasonal flu |
| gptkbp:community_impact |
promotes herd immunity
|
| gptkbp:contraindication |
severe allergic reaction to vaccine components
consult healthcare provider before use |
| gptkbp:dosage_form |
suspension
|
| gptkbp:formulation |
gptkb:item
|
| gptkbp:frequency |
gptkb:annually
|
| gptkbp:healthcare |
provided with each dose
|
| https://www.w3.org/2000/01/rdf-schema#label |
Fluarix
|
| gptkbp:ingredients |
inactivated influenza virus
|
| gptkbp:is_standardized_by |
follow CDC recommendations
|
| gptkbp:is_used_for |
influenza prevention
|
| gptkbp:is_vulnerable_to |
global
varies by location varies by season refrigerated ongoing improvements quadrivalent high-risk populations updated annually introduced in 2005 available in pharmacies adverse event reporting system depends on match with circulating strains trained healthcare provider CDC recommends for all ages based on previous strains before flu season reduces flu-related hospitalizations |
| gptkbp:manager |
intramuscular injection
|
| gptkbp:manufacturer |
gptkb:Glaxo_Smith_Kline
|
| gptkbp:market |
ongoing
|
| gptkbp:origin |
gptkb:Belgium
|
| gptkbp:packaging |
single-dose vials
|
| gptkbp:public_awareness |
conducted by health organizations
|
| gptkbp:safety_features |
generally well-tolerated
|
| gptkbp:shelf_life |
24 months
|
| gptkbp:side_effect |
fatigue
headache muscle pain fever pain at injection site anaphylaxis (rare) |
| gptkbp:storage |
2 to 8 degrees Celsius
|
| gptkbp:target_audience |
adults and children
|
| gptkbp:type |
inactivated influenza vaccine
|
| gptkbp:type_of_insurance |
often covered by insurance
|
| gptkbp:updates |
annual reformulation
|
| gptkbp:bfsParent |
gptkb:Glaxo_Smith_Kline
|
| gptkbp:bfsLayer |
3
|